CIK 0001840229
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MiNK Therapeutics, Inc.
Sign in to watch- Ticker
- INKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 212-994-8250
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
- 4 Open-market buy 10% owner bought 45,426 shares at an average $1.47 ($66,644)
- 4 Open-market sale Director sold 100,000 shares at $0.95 ($94,850)
- 4 Open-market buy 10% owner bought 250,362 shares at an average $1.04 ($260,189)
- 4 Open-market buy Director bought 100,000 shares at $0.95 ($94,850)
- 4 Other disposition 10% owner disposed of 4,988,273 shares (other)
- 4 Grant or award Director acquired 6,699 shares (grant or award)
- 4 Grant or award Director acquired 8,553 shares (grant or award)
- 4 Grant or award Director acquired 6,878 shares (grant or award)
- 4 Grant or award Director acquired 8,493 shares (grant or award)
- 4 Grant or award Director acquired 7,357 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Scientific Officer acquired 51,628 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 171,990 shares (grant or award)
- 4 Grant or award Director acquired 5,364 shares (grant or award)
- 4 Grant or award Director acquired 5,508 shares (grant or award)
- 4 Grant or award Director acquired 6,849 shares (grant or award)
- 4 Grant or award Director acquired 6,801 shares (grant or award)
- 4 Grant or award Director acquired 5,891 shares (grant or award)
- 4 Grant or award Director acquired 10,974 shares (grant or award)
Page 6 of 8 · 145 filings